Avascent

Avascent is a strategy and management consulting firm focused primarily on aerospace, defense, and other government-driven markets rather than a drug-development or healthcare operating company. The firm has provided advisory services in strategic growth, value capture, mergers and acquisitions support, and related consulting areas for corporate clients and financial investors. In November 2022, Oliver Wyman, a business of Marsh McLennan, announced completion of its acquisition of Avascent. Avascent has also been described as serving sectors including aerospace, defense, homeland security, logistics, infrastructure, and certain adjacent government-influenced markets. For biotech analysts, the key takeaway is that this is not a life sciences developer, platform biotech, pharma company, CRO, or CDMO, but a consulting business with some exposure to healthcare clients in broader market-facing materials.